LXRX
Price
$0.36
Change
-$0.03 (-7.69%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
130.06M
51 days until earnings call
SPRO
Price
$0.76
Change
-$0.02 (-2.56%)
Updated
Mar 10, 04:42 PM (EDT)
Capitalization
42.47M
2 days until earnings call
Ad is loading...

LXRX vs SPRO

Header iconLXRX vs SPRO Comparison
Open Charts LXRX vs SPROBanner chart's image
Lexicon Pharmaceuticals
Price$0.36
Change-$0.03 (-7.69%)
Volume$63.06K
Capitalization130.06M
Spero Therapeutics
Price$0.76
Change-$0.02 (-2.56%)
Volume$100
Capitalization42.47M
LXRX vs SPRO Comparison Chart
Loading...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. SPRO commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Buy and SPRO is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (LXRX: $0.39 vs. SPRO: $0.78)
Brand notoriety: LXRX and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 197% vs. SPRO: 73%
Market capitalization -- LXRX: $130.06M vs. SPRO: $42.47M
LXRX [@Biotechnology] is valued at $130.06M. SPRO’s [@Biotechnology] market capitalization is $42.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than LXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRO’s TA Score shows that 2 TA indicator(s) are bullish.

  • SPRO’s TA Score: 2 bullish, 3 bearish.

Price Growth

LXRX (@Biotechnology) experienced а -43.99% price change this week, while SPRO (@Biotechnology) price change was +0.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

LXRX is expected to report earnings on May 01, 2025.

SPRO is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($130M) has a higher market cap than SPRO($42.5M). SPRO YTD gains are higher at: -24.369 vs. LXRX (-46.947). SPRO has higher annual earnings (EBITDA): -2.45M vs. LXRX (-198.7M). LXRX has more cash in the bank: 258M vs. SPRO (76.3M). SPRO has less debt than LXRX: SPRO (4.62M) vs LXRX (101M). SPRO has higher revenues than LXRX: SPRO (89.9M) vs LXRX (5.23M).
LXRXSPROLXRX / SPRO
Capitalization130M42.5M306%
EBITDA-198.7M-2.45M8,120%
Gain YTD-46.947-24.369193%
P/E RatioN/A9.50-
Revenue5.23M89.9M6%
Total Cash258M76.3M338%
Total Debt101M4.62M2,185%
FUNDAMENTALS RATINGS
LXRX vs SPRO: Fundamental Ratings
LXRX
SPRO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9776
PRICE GROWTH RATING
1..100
9789
P/E GROWTH RATING
1..100
206
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (44) in the Pharmaceuticals Major industry is in the same range as LXRX (56) in the Biotechnology industry. This means that SPRO’s stock grew similarly to LXRX’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LXRX (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to LXRX’s over the last 12 months.

SPRO's SMR Rating (76) in the Pharmaceuticals Major industry is in the same range as LXRX (97) in the Biotechnology industry. This means that SPRO’s stock grew similarly to LXRX’s over the last 12 months.

SPRO's Price Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as LXRX (97) in the Biotechnology industry. This means that SPRO’s stock grew similarly to LXRX’s over the last 12 months.

SPRO's P/E Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as LXRX (20) in the Biotechnology industry. This means that SPRO’s stock grew similarly to LXRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPRO
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLPSX86.360.73
+0.85%
ProFunds Mid Cap Value Svc
BSFIX31.200.20
+0.65%
Baron Small Cap Instl
CFIGX14.110.08
+0.57%
Columbia Flexible Capital Income C
ORSAX14.130.02
+0.14%
North Square Dynamic Sm Cp A
JEVNX9.16N/A
N/A
JHancock Disciplined Value Em Mkts EqNAV

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with FRTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then FRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+6.55%
FRTX - LXRX
41%
Loosely correlated
N/A
OCUL - LXRX
39%
Loosely correlated
+2.72%
ABOS - LXRX
38%
Loosely correlated
+0.81%
VCYT - LXRX
37%
Loosely correlated
-1.51%
EPIX - LXRX
36%
Loosely correlated
-1.20%
More

SPRO and

Correlation & Price change

A.I.dvisor tells us that SPRO and BCAB have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPRO and BCAB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-1.14%
BCAB - SPRO
32%
Poorly correlated
+4.83%
GNPX - SPRO
29%
Poorly correlated
+1.49%
BDTX - SPRO
29%
Poorly correlated
-1.05%
RAPT - SPRO
28%
Poorly correlated
+0.89%
VCYT - SPRO
28%
Poorly correlated
-1.51%
More